ALLMedicine™ Angiosarcoma Of The Scalp Center
Research & Reviews 19 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663818
Medicine Suzuki G, Masui K et. al.
Dec 11th, 2021 - Angiosarcoma of the scalp (ASS) is a rare solid tumor with a high risk of local recurrence. Effective treatment strategies are not currently available for angiosarcoma of the scalp (ASS). The aim of this study was to report the utility of high-dos...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447824
The Neuroradiology Journal; Kawaguchi M, Kato H et. al.
Mar 5th, 2021 - This study aimed to evaluate imaging findings of cutaneous angiosarcoma (cAS) of the scalp compared with those of cutaneous squamous cell carcinoma (cSCC). This study included 15 patients with primary cAS and 10 with primary cSCC of the scalp. Sev...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871283
Technology in Cancer Research & Treatment; Mizuno T, Tomita N et. al.
Feb 2nd, 2021 - We compared radiotherapy plans among helical tomotherapy (HT), volumetric-modulated arc therapy (VMAT), and intensity-modulated proton therapy (IMPT) for angiosarcoma of the scalp (AS). We conducted a planning study for 19 patients with AS. The cl...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367225
Radiation Oncology (London, England); Inui S, Ueda Y et. al.
Jul 19th, 2020 - Total scalp irradiation presents technical and dosimetric challenges. While reports suggest that HyperArc, a new stereotactic radiosurgery planning technique applied to non-coplanar volumetric-modulated arc therapy (VMAT) technique, is associated ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359578
BMC Cancer; Oashi K, Shibata T et. al.
Jul 15th, 2020 - Paclitaxel is a standard of care for patients with primary cutaneous angiosarcoma of the scalp and face. However, no standard second-line treatment for paclitaxel-resistant patients has ever been established. Since primary cutaneous angiosarcoma e...
